Last reviewed · How we verify
NCT03900533
Emotion Regulation Group Skills Training for Adolescents and Parents
NA trial testing Adjunctive group emotion regulation skills training in Behavioral Symptoms in 119 participants. Completed in 4 September 2023.
4 September 2023
Quick facts
| Lead sponsor | Region Östergötland |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 119 |
| Start date | 2 April 2019 |
| Primary completion | 4 September 2023 |
| Estimated completion | 4 September 2023 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Adjunctive group emotion regulation skills training
- Treatment as usual
Conditions studied
- Behavioral Symptoms — all drugs for Behavioral Symptoms →
- Emotional Instability — all drugs for Emotional Instability →
Sponsor
Region Östergötland
Who can join
Adults 14 to 17, any sex, with Behavioral Symptoms or Emotional Instability. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate if emotion regulation group therapy skills training for adolescents and parents is an efficacious treatment when delivered as adjunctive to treatment as usual compared to a control group consisting of treatment as usual.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emotion regulation skills training for adolescents and parents in a clinical setting: a randomised controlled trial.
Holmqvist Larsson K, Falkenström F, Andersson G, Stern H, et al · · 2026 · PMID 42210292 · DOI 10.1186/s13034-026-01098-1
Verify or expand the search:
- PubMed search for NCT03900533
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Behavioral Symptoms
Currently open trials in the same condition.
- NCT06511908 — Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resi · Phase 2 · recruiting
- NCT06462196 — Natural History of Depression, Bipolar Disorder and Suicide Risk · recruiting
- NCT06105736 — Regulating Together in Tuberous Sclerosis Complex · NA · recruiting
- NCT05322343 — Biobank and Brain Health in Bordeaux. · recruiting
- NCT06225661 — Focused Suicide Prevention Strategy for Youth Presenting to the Emergency Department With Suicide Related Behaviour · NA · active not recruiting
Other Region Östergötland trials
Trials by the same sponsor.
- NCT06346535 — PrimeCog: Primary Care Cognitive Testing · recruiting
- NCT06276192 — Digital Physiotherapy Treatment for Patients With Subacromial Pain Compared to Usual Physiotherapy in Primary Care · NA · not yet recruiting
- NCT07159516 — Identifying Birth-Related PTSD: Cutoffs for the City Birth Trauma Scale · completed
- NCT06659822 — Responding to Elder Abuse in GERiAtric Care - Dementia · completed
- NCT05782582 — Chronic Coronary Syndrome in Swedish Primary Care · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03900533 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Östergötland
- Last refreshed: 29 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03900533.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing